Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from the company. Its shares aren't exactly cheap at recent levels, though. If ...

A daily dose of blarcamesine restored autophagy among patients with early Alzheimer’s disease, with improved outcomes through 192 weeks, according to an abstract presented at the Alzheimer’s ...

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Eli Lilly had profit of $10 billion in 2024. It could afford its Wisconsin project without Evers' $100 million tax credits ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 ...

Health-care companies ticked up as traders rotated back into the beaten-down sector. Shares of Eli Lilly and UnitedHealth Group, among other companies that have recently seen major downdrafts in their ...

The up to $100 million in state tax incentives for a $3 billion Eli Lilly expansion in Kenosha County isn’t the only tax ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...